Previous close | 2.8900 |
Open | 2.9100 |
Bid | 3.1200 x 100 |
Ask | 3.2400 x 100 |
Day's range | 2.8300 - 3.2000 |
52-week range | 2.5000 - 11.1100 |
Volume | |
Avg. volume | 86,342 |
Market cap | 119.894M |
Beta (5Y monthly) | 1.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer’s disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial re
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive interim IGNITE Phase 2 data demonstrating iluzanebart (VGL101) as potential disease-modifying therapy for ALSP WATERTOWN, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today anno
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer clinical trial evaluating VG-3927 ongoing; Interim data analysis on track for mid-2024 – – Appointed biotech industry executive Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer – WATERTOWN, Mass., March 26, 2024